Nama's AI scorecard currently rates NovoCure Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does NVCR report earnings?

NovoCure's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.24.

What is the NVCR price target?

The median analyst price target from 7 analysts is $20.00, with a range of $15.00 – $52.00.

Is NVCR Shariah compliant?

Nama's AAOIFI-style screen reads NovoCure as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

NovoCure (NVCR)

Healthcare · Medical Devices · NASDAQ

NovoCure (NVCR) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.55B and a free-cash-flow yield of -5.1%. Over the most recent reported fiscal year, revenue grew 8.3%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 3.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +30.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-88.9%

How far the last close sits under the highest price of the past five years.

Market cap	$1.55B
Trailing P/E	—
Price / book	4.6
Price / sales	2.1
FCF yield	-5.1%
Dividend yield	—
Gross margin	76.1%
Operating margin	-22.1%
Net margin	-21.2%
Revenue growth (YoY)	+8.3%
Revenue growth (3-yr annual)	+6.8%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

NVCR earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.24). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$0.09	-$0.23	+60.9%	$193.40M
Q2 2026	Jul 23, 2026	-$0.13	-$0.33	+60.6%	$183.58M
Q1 2026	Apr 30, 2026	-$0.62	-$0.51	-21.6%	$174.06M
Q4 2025	Feb 26, 2026	-$0.22	-$0.41	+46.3%	$174.35M

NVCR analyst price target

Median target $20.00 from 7 analysts, ranging $15.00 – $52.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live NVCR data on Nama Insights →

NVCR FAQ

Is NVCR a buy?: Nama's AI scorecard currently rates NovoCure Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does NVCR report earnings?: NovoCure's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.24.
What is the NVCR price target?: The median analyst price target from 7 analysts is $20.00, with a range of $15.00 – $52.00.
Is NVCR Shariah compliant?: Nama's AAOIFI-style screen reads NovoCure as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.